Urology Today.net

Site updated at Thursday, 12 May 2016

Common Urological Problems


FDA Approves Xtandi for Late-Stage Castration-Resistant Prostate Cancer

The U.S. Food and Drug Administration today approved Xtandi (enzalutamide) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.

Approved for prostate cancer patients previously treated with docetaxel, another anti-cancer treatment, Xtandi was reviewed under the FDA’s priority review program.… FDA Approves Xtandi for Late-Stage Castration-Resistant Prostate Cancer   

altered appetite1 - radiation therapy oncology group1 - cardiovascular issues1 - renal medulla1 - renal calyx1 - robot-assisted surgery for prostate cancer1 - high blood sugar1 - health care1 - aua1 - renal dysplasia1 - serum urea nitrogen1 - recurrent kidney stones1 - critical care1 - overweight1 - renal transplantation3 - cprs1 - invasive urologic surgery1 - monosomy1 - congenital malformations of the kidney1 - intermittent therapy1 - prostate cells1 - niaid1 - autoimmune kidney disorder1 - urate nephropathy1 - hepatolenticular degeneration1 - prognostic indicator1 - prostate inflammation1 - dstyk1 - bladder control4 - kidney abnormality1 -